Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Nav

General Info

Email
Print

Geography

Argentina (ARG)

Australia (AUS)

Austria (AUT)

Belgium (BEL)

Brazil (BRA)

Canada (CAN)

China (CHN)

Hong Kong

Denmark (DNK)

Åland Islands

France (FRA)

Germany (DEU)

Hungary (HUN)

Israel (ISR)

Italy (ITA)

Malaysia (MYS)

Mexico (MEX)

Netherlands (NLD)

New Zealand (NZL)

Poland (POL)

Portugal (PRT)

Singapore (SGP)

Sweden (SWE)

Taiwan (Province of China) (TWN)

Trinidad and Tobago (TTO)

Port of Spain

United Kingdom (GBR)

United States of America (USA)

Puerto Rico

Finland (FIN)

View all

Time period covered

01/1996 - 12/2000

Data type

Scientific literature

Keywords

Cardiovascular and circulatory diseases

Citation

Authors

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group

Journal

N Engl J Med

Volume

345

Issue

12

Pages

851-60

Publication year

2001

Suggested citation

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12): 851-60.

GHDx Entry last modified on: Jan 3, 2024